The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Magnetic iron oxide nanoparticles for brain imaging and drug delivery
Open accessAbstract
Central nervous system (CNS) disorders affect as many as 1.5 billion people globally. The limited delivery of most imaging and therapeutic agents into the brain is a major challenge for treatment of CNS disorders. With the advent of nanotechnologies, controlled delivery of drugs with nanoparticles holds great promise in CNS disorders for overcoming the blood-brain barrier (BBB) and improving delivery efficacy. In recent years, magnetic iron oxide nanoparticles (MIONPs) have stood out as a promising theranostic nanoplatform for brain imaging and drug delivery as they possess unique physical properties and biodegradable characteristics. In this review, we summarize the recent advances in MIONP-based platforms as imaging and drug delivery agents for brain diseases. We firstly introduce the methods of synthesis and surface functionalization of MIONPs with emphasis on the inclusion of biocompatible polymers that allow for the addition of tailored physicochemical properties. We then discuss the recent advances in in vivo imaging and drug delivery applications using MIONPs. Finally, we present a perspective on the remaining challenges and possible future directions for MIONP-based brain delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Campisi, M., Shin, Y., Osaki, T., Hajal, C., Chiono, V., & Kamm, R. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.014 · Cited by 718
Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications
Qiao, R., Yang, C., & Gao, M. (2009) · Journal of Materials Chemistry · doi:10.1039/b902394a · Cited by 685
Self-citationA Decade of the Protein Corona
Ke, P. C., Lin, S., Parak, W. J., Davis, T. P., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b08008 · Cited by 672
Self-citationVatine, G. D., Barrile, R., Workman, M. J., Sances, S., Barriga, B. K., Rahnama, M., Barthakur, S., Kasendra, M., Lucchesi, C., Kerns, J., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.011 · Cited by 632
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma
Jordan, A., Scholz, R., Maier-Hauff, K., van Landeghem, F. K. H., Waldoefner, N., Teichgraeber, U., Pinkernelle, J., Bruhn, H., Neumann, F., Thiesen, B., et al. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9059-z · Cited by 459
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
Why animal studies are often poor predictors of human reactions to exposure
Bracken, M. B. (2009) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.08k033 · Cited by 362
Synthesis of phase-pure and monodisperse iron oxide nanoparticles by thermal decomposition
Hufschmid, R., Arami, H., Ferguson, R. M., Gonzales, M., Teeman, E., Brush, L. N., Browning, N. D., & Krishnan, K. M. (2015) · Nanoscale · doi:10.1039/c5nr01651g · Cited by 341
Brain-targeted drug delivery by manipulating protein corona functions
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334
Blood-brain barrier opening with focused ultrasound in Parkinson’s disease dementia
Gasca-Salas, C., Fernández-Rodríguez, B., Pineda-Pardo, J. A., Rodríguez-Rojas, R., Obeso, I., Hernández-Fernández, F., del Álamo, M., Mata, D., Guida, P., Ordás-Bandera, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21022-9 · Cited by 319
Cole, A. J., David, A. E., Wang, J., Galbán, C. J., Hill, H. L., & Yang, V. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.040 · Cited by 308
Yu, M., Huang, S., Yu, K. J., & Clyne, A. M. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13055554 · Cited by 308
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280
Blood–brain barrier leakage is increased in parkinson’s disease
Al-Bachari, S., Naish, J. H., Parker, G. J. M., Emsley, H. C. A., & Parkes, L. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.593026 · Cited by 263
Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy
Rassu, G., Soddu, E., Posadino, A. M., Pintus, G., Sarmento, B., Giunchedi, P., & Gavini, E. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.01.031 · Cited by 239
Mouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
Intrathecal drug delivery in the era of nanomedicine
Fowler, M. J., Cotter, J. D., Knight, B. E., Sevick-Muraca, E. M., Sandberg, D. I., & Sirianni, R. W. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.006 · Cited by 187
Role of the methoxy group in immune responses to mPEG-protein conjugates
Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200551b · Cited by 185
Yang, J., Zaim Wadghiri, Y., Minh Hoang, D., Tsui, W., Sun, Y., Chung, E., Li, Y., Wang, A., de Leon, M., & Wisniewski, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.023 · Cited by 135
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114
Remya, N. S., Syama, S., Sabareeswaran, A., & Mohanan, P. V. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.119 · Cited by 97
Enabling peristalsis of human colon tumor organoids on microfluidic chips
Fang, G., Lu, H., Al-Nakashli, R., Chapman, R., Zhang, Y., Ju, L. A., Lin, G., Stenzel, M. H., & Jin, D. (2022) · Biofabrication · doi:10.1088/1758-5090/ac2ef9 · Cited by 77
Drug targeting strategies into the brain for treating neurological diseases
Barnabas, W. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.015 · Cited by 70
Liu, X.-G., Zhang, L., Lu, S., Liu, D.-Q., Zhang, L.-X., Yu, X.-L., & Liu, R.-T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s240953 · Cited by 55
Karmali, P. P., Chao, Y., Park, J.-H., Sailor, M. J., Ruoslahti, E., Esener, S. C., & Simberg, D. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200375x · Cited by 36
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review
Al-Thani, A. N., Jan, A. G., Abbas, M., Geetha, M., & Sadasivuni, K. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122899 · Cited by 323
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Vasić, K., Knez, Ž., & Leitgeb, M. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15080227 · Cited by 76
Metadata
- Authors
- Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 197
- Pages
- 114822
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4366607032
- Cited by
- 245
- References
- 37
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.